Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, and Immune Cell Function and Interaction.
Discovery, delineation, and therapeutic targeting of a hyper-translation pathway driving cytokine release syndrome.
A compass in the challenge: the CALLY index as a prognostic biomarker in advanced cholangiocarcinoma treated with chemoimmunotherapy: a retrospective propensity score-matched cohort study.
CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.
Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.
Manganese mediates nucleoplasm distribution of cGAS to enhance systemic antitumor immunity and drive abscopal effect.
Intrinsic NPRL2 and NPRL3 regulate the sensitivity of B-cell malignancies to CAR-T cell therapy.
DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling.
Antitumor effects of STING agonists on nervous system tumors via tumor-intrinsic STING-STAT1-mediated HMGN2 expression.
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.
MCT1 inhibition remodels the tumor immune microenvironment for enhanced cancer immunotherapy.
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy.
CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation.
Epi-Immunotherapy in Cancer Treatment: Mechanisms, Clinical Progress, and Future Directions.
Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma.
Synthesis, function, and therapeutic potential of glycosphingolipids.
Dual-Faced Role of GDF6 in Cancer: Mechanistic Insights into Its Context-Dependent Regulation of Metastasis and Immune Evasion Across Human Malignancies.
Platelet-to-Neutrophil Ratio: A Novel Prognostic Indicator for Anti-PD-1-Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors.
PSMB9 Orchestrates Tumor Immune Landscape and Serves as a Potent Biomarker for Prognosis and T Cell-Based Immunotherapy Response.
Hyponatremia predicts immunotherapy resistance in biliary tract cancer.
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.
Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma.
Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
Manganese boosts natural killer cell function via cGAS-STING mediated UTX expression.
Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma
Manganese primed immunochemotherapy in platinum-resistant/refractory ovarian cancer: a randomized, single-blind, placebo-controlled, phase 2 trial
Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models.
Characteristics of premanufacture CD8<sup>+</sup>T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma.
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.